Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Preventive Medicine Reports|February 4, 2021
BMI trajectories after primary school-based lifestyle intervention: Unravelling an uncertain future. A mixed methods studyMarije Oosterhoff, Shahab Jolani, Daisy De Bruijn-Geraets, et al.
BMC Public Health|December 10, 2020
Lifetime cost-effectiveness and equity impacts of the Healthy Primary School of the Future initiativeMarije Oosterhoff, Eelco A B Over, Anoukh van Giessen, et al.
Social Science & Medicine (1982)|January 23, 2023
Estimating the health impact of delayed elective care during the COVID -19 pandemic in the NetherlandsMarije Oosterhoff, Lisanne H J A Kouwenberg, Adriënne H Rotteveel, et al.
Pharmacoeconomics|November 28, 2017
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert Wolff, Anoukh van Giessen, et al.
Cardiovascular Diabetology|March 23, 2016
Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetesAnoukh van Giessen, Leandra J M Boonman-de Winter, Frans H Rutten, et al.
Pharmacoeconomics|February 27, 2018
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert F Wolff, Xavier Pouwels, et al.
Pharmacoeconomics|June 10, 2023
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP RegistryXinyu Li, Rudolf Hoogenveen, Mohamed El Alili, et al.
Pharmacoeconomics|January 19, 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology AppraisalXavier G L V Pouwels, Robert Wolff, Bram L T Ramaekers, et al.
Diabetologia|April 16, 2024
Trajectories of clinical characteristics, complications and treatment choices in data-driven subgroups of type 2 diabetesXinyu Li, Louise A Donnelly, Roderick C Slieker, et al.
Pharmacoeconomics|April 13, 2024
A Blueprint for Multi-use Disease Modeling in Health Economics: Results from Two Expert-Panel ConsultationsJunfeng Wang, Xavier Pouwels, Bram Ramaekers, et al.
Pageof 3